by Virtus | Oct 11, 2026 | Scientific Advisory Board
Professor Nathan Bartlett Viral Immunologist Professor Nathan W. Bartlett is a leading Australian viral immunologist with over two decades of experience translating fundamental discoveries in respiratory virus biology into clinical and industry applications. He is...
by Virtus | Sep 5, 2026 | Uncategorized
Pharmacodynamic endpoints are an important part of respiratory drug development, helping researchers understand how a therapeutic candidate affects its biological target and produces a measurable response. While pharmacokinetic studies investigate what the body does...
by Virtus | Sep 5, 2026 | Respiratory Preclinical Research
Respiratory toxicology studies are an important component of preclinical drug development, particularly when a therapeutic is intended to treat diseases of the lungs and airways or is administered directly to the respiratory tract. Before a new respiratory therapeutic...
by Virtus | Sep 5, 2026 | Respiratory Preclinical Research
IND-enabling respiratory studies are an important part of the preclinical drug development process for new respiratory therapeutics. Before a potential treatment can progress into human clinical trials, pharmaceutical and biotechnology companies need appropriate...
by Virtus | Sep 4, 2026 | Respiratory Preclinical Research
Respiratory pharmacology is an important field of pharmaceutical research focused on understanding how medicines interact with the respiratory system and how therapeutic compounds can be developed to treat diseases affecting the lungs and airways. From asthma and...